🟢 New in Current Filing We may not be able to increase or maintain CASGEVY product revenues. 🔒

🟢 New in Current Filing revenues, and results of operations. 🔒

🟢 New in Current Filing Competing products and technological advances from our competitors may negatively affect our business and market 🔒

🟢 New in Current Filing non-monetary remedies. 🔒

🟢 New in Current Filing information. 🔒

🟢 New in Current Filing If we are not able to operate without infringing upon intellectual property rights of third parties, our business could be 🔒

🟢 New in Current Filing including at our third-party providers. 🔒

🟢 New in Current Filing product candidates and manufacture our products would be harmed. 🔒

🟢 New in Current Filing Reliance on third-party relationships could adversely affect our business. 🔒

🟢 New in Current Filing adversely affect our business. 🔒

🟢 New in Current Filing may be delays or failures in realizing the anticipated benefits of these activities. 🔒

🟢 New in Current Filing of operations and financial condition. 🔒

🟢 New in Current Filing Our stock price is volatile. 🔒

🟢 New in Current Filing SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 🔒

🟢 New in Current Filing ISSUER PURCHASES OF EQUITY SECURITIES 🔒

🟢 New in Current Filing Issuer Repurchases of Equity Securities 🔒

🟢 New in Current Filing Programs (1) 🔒

🟢 New in Current Filing Financial Highlights 🔒

🟢 New in Current Filing Business Updates 🔒

🟢 New in Current Filing Our Business Environment 🔒

🟢 New in Current Filing Strategic Transactions 🔒

🟢 New in Current Filing Total Revenues 🔒

🟢 New in Current Filing (in millions, except percentages) 🔒

🟢 New in Current Filing Operating Costs and Expenses 🔒

🟢 New in Current Filing (in millions, except percentages) 🔒

🟢 New in Current Filing Non-Operating Income (Expense), Net 🔒

🟢 New in Current Filing LIQUIDITY AND CAPITAL RESOURCES 🔒

🟢 New in Current Filing (in millions, except percentages) 🔒

🟢 New in Current Filing Working Capital 🔒

🟢 New in Current Filing (in millions) 🔒

🟢 New in Current Filing Sources and Uses of Liquidity 🔒

🟢 New in Current Filing Future Capital Requirements 🔒

🟢 New in Current Filing CRITICAL ACCOUNTING POLICIES AND ESTIMATES 🔒

🟢 New in Current Filing Revenue Recognition 🔒

🟢 New in Current Filing (in millions) 🔒

🟢 New in Current Filing Acquisitions 🔒

🟢 New in Current Filing Pre-Launch Inventories 🔒

🟢 New in Current Filing Income Taxes 🔒

🟢 New in Current Filing RECENT ACCOUNTING PRONOUNCEMENTS 🔒

🟢 New in Current Filing Interest Rate Risk 🔒

🟢 New in Current Filing Foreign Exchange Market Risk 🔒

🟢 New in Current Filing FINANCIAL DISCLOSURE 🔒

🟢 New in Current Filing (2) Management’s Annual Report on Internal Control Over Financial Reporting. Management is responsible for 🔒

🟢 New in Current Filing (4) Report of Independent Registered Public Accounting Firm 🔒

🟢 New in Current Filing Opinion on Internal Control Over Financial Reporting 🔒

🟢 New in Current Filing Basis for Opinion 🔒

🟢 New in Current Filing Definition and Limitations of Internal Control Over Financial Reporting 🔒

🟢 New in Current Filing Subject to Trading 🔒

🟢 New in Current Filing RELATED STOCKHOLDER MATTERS 🔒

🟢 New in Current Filing this Form 10-K 🔒

🟢 New in Current Filing Governance Documents 🔒

🟢 New in Current Filing Stock Certificate 🔒

🟢 New in Current Filing Collaboration Agreement 🔒

🟢 New in Current Filing SEC File/Reg. Number 🔒

🟢 New in Current Filing Financing Agreements 🔒

🟢 New in Current Filing Equity Plans 🔒

🟢 New in Current Filing Agreements with Executive Officers and Directors 🔒

🟢 New in Current Filing SEC File/Reg. Number 🔒

🟢 New in Current Filing Insider Trading Policy 🔒

🟢 New in Current Filing Subsidiaries 🔒

🟢 New in Current Filing Certifications 🔒

🟢 New in Current Filing Clawback Policy 🔒

🟢 New in Current Filing SEC File/Reg. Number 🔒

🟢 New in Current Filing Vertex Pharmaceuticals Incorporated 🔒

🟢 New in Current Filing Report of Independent Registered Public Accounting Firm 🔒

🟢 New in Current Filing Opinion on the Financial Statements 🔒

🟢 New in Current Filing Basis for Opinion 🔒

🟢 New in Current Filing Critical Audit Matter 🔒

🟢 New in Current Filing Medicaid Drug Rebate Program in the U.S. 🔒

🟢 New in Current Filing (in millions, except per share amounts) 🔒

🟢 New in Current Filing Year Ended December 31, 🔒

🟢 New in Current Filing (in millions) 🔒

🟢 New in Current Filing Year ended December 31, 🔒

🟢 New in Current Filing (in millions, except share and per share data) 🔒

🟢 New in Current Filing December 31, 🔒

🟢 New in Current Filing Liabilities and Shareholders’ Equity 🔒

🟢 New in Current Filing (in millions) 🔒

🟢 New in Current Filing Balance at December 31, 2022 🔒

🟢 New in Current Filing Balance at December 31, 2023 🔒

🟢 New in Current Filing Balance at December 31, 2024 🔒

🟢 New in Current Filing Balance at December 31, 2025 🔒

🟢 New in Current Filing (in millions) 🔒

🟢 New in Current Filing Year Ended December 31, 🔒

🟢 New in Current Filing Notes to Consolidated Financial Statements 🔒

🟢 New in Current Filing Nature of Business and Accounting Policies 🔒

🔴 No Match in Current Filing SUMMARY OF RISK FACTORS 🔒

🔴 No Match in Current Filing Risks Related to Our Business 🔒

🔴 No Match in Current Filing Risks Related to Pricing of Our Products 🔒

🔴 No Match in Current Filing Risks Related to Development and Clinical Testing of Our Products and Product Candidates 🔒

🔴 No Match in Current Filing Risks Related to Government Regulation 🔒

🔴 No Match in Current Filing Risks Related to Supply, Manufacturing and Reliance on Third Parties 🔒

🔴 No Match in Current Filing Risks Related to Business Development Activities 🔒

🔴 No Match in Current Filing Risks Related to Intellectual Property 🔒

🔴 No Match in Current Filing Risks Related to Our Operations 🔒

🔴 No Match in Current Filing Risks Related to Financial Results and Holding Our Common Stock 🔒

🔴 No Match in Current Filing If we are unable to successfully develop, obtain approval and commercialize treatments for acute and neuropathic pain, our business could be materially harmed. 🔒

🔴 No Match in Current Filing If we are not successful in commercializing CASGEVY, our revenue growth could be limited and our business could be materially harmed. 🔒

🔴 No Match in Current Filing If our competitors bring products with superior product profiles to market, our products may not be competitive, and our revenues could decline. 🔒

🔴 No Match in Current Filing If physicians and patients do not accept our products, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would decline in future periods. 🔒

🔴 No Match in Current Filing Cell and genetic therapies face increased scrutiny from the public and medical communities and commercial success will depend, in part, upon the acceptance of those communities. 🔒

🔴 No Match in Current Filing Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to provide coverage and adequate reimbursement rates for our products, our revenues will be harmed. 🔒

🔴 No Match in Current Filing We may experience pricing pressure on our products, which could reduce our revenues and future profitability. 🔒

🔴 No Match in Current Filing Current health care laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. health care system may affect our ability to commercialize our marketed products profitably. 🔒

🔴 No Match in Current Filing We have experienced challenges commercializing products outside of the U.S., and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products in ex-U.S. markets. 🔒

🔴 No Match in Current Filing Insurance coverage and reimbursement of cell and genetic therapies is uncertain. 🔒

🔴 No Match in Current Filing If we are unable to obtain or are delayed in obtaining regulatory approval, we may incur additional costs, experience delays, or be unable to commercialize our product candidates. 🔒

🔴 No Match in Current Filing If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the product candidate could increase and the competitive position of the product candidate could be adversely affected. 🔒

🔴 No Match in Current Filing Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval. 🔒

🔴 No Match in Current Filing Enrollment for clinical trials for our cell and gene therapies may face additional and unique challenges and adverse developments associated with these clinical trials could result in action by regulatory bodies, including revised requirements for approval. 🔒

🔴 No Match in Current Filing If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions, and fines that could have a material adverse effect on our business, financial condition, results of operations and growth prospects. 🔒

🔴 No Match in Current Filing If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our product candidates. 🔒

🔴 No Match in Current Filing The regulatory approval process for our cell or genetic therapies involves additional consultations with regulatory agencies, costs, and potentially longer timelines as compared to those for small molecules. 🔒

🔴 No Match in Current Filing If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. 🔒

🔴 No Match in Current Filing We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements. 🔒

🔴 No Match in Current Filing We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and product candidates. 🔒

🔴 No Match in Current Filing Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities. 🔒

🔴 No Match in Current Filing We may not realize the anticipated benefits of existing or future acquisitions of businesses or technologies, and the integration following any such acquisition may disrupt our business and management. 🔒

🔴 No Match in Current Filing If our patents do not protect our products or our products infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products, substantial damages, or circumvention of our patents by third parties. 🔒

🔴 No Match in Current Filing Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes that are inherently costly and unpredictable. 🔒

🔴 No Match in Current Filing We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. 🔒

🔴 No Match in Current Filing A variety of risks associated with operating in foreign countries could materially adversely affect our business. 🔒

🔴 No Match in Current Filing We rely on third parties to carry out our operations. Failure to maintain our third-party relationships or challenges at or with these third parties could materially harm our business. 🔒

🔴 No Match in Current Filing Our stock price may fluctuate. 🔒

🔴 No Match in Current Filing Our quarterly operating results are subject to significant fluctuation. 🔒

🔴 No Match in Current Filing We expect that results from our clinical development activities and the clinical development activities of our competitors will continue to be released periodically, and may result in significant volatility in the price of our common stock. 🔒

🔴 No Match in Current Filing Issuances of additional shares of our common stock could cause the price of our common stock to decline. 🔒

🔴 No Match in Current Filing There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices. 🔒

🟡 Modified combinations involving us. 🔒

🟡 Modified taxable income. 🔒

🟡 Modified occurring at our facilities. 🔒

🟡 Modified If we fail to scale our operations to accommodate growth, our business may suffer. 🔒

🟡 Modified impose restrictions on our business. 🔒

🟡 Modified We are subject to various and evolving laws and regulations governing the privacy and security of personal data. 🔒

🟡 Modified If we fail to attract and retain skilled employees, our business could be materially harmed. 🔒

🟡 Modified The use of social media platforms presents risks and challenges. 🔒

🟡 Modified Our success depends on our ability to develop and commercialize additional medicines. 🔒

🟡 Modified negatively affected, the approved product could lose its approval, and our business could be materially harmed. 🔒

🟡 Modified A variety of risks associated with operating in foreign countries could materially adversely affect our business. 🔒

🟡 Modified commercialization of our approved products. 🔒

🟡 Modified Our business is substantially dependent on the success of our CF medicines. 🔒

🟡 Modified Our business has a substantial risk of product liability claims and other litigation liability. 🔒

🟡 Modified There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable 🔒

🟡 Modified If we fail to successfully conduct our clinical activities, our clinical trials or future regulatory approvals may be delayed or 🔒

🟡 Modified If we are unable to obtain, maintain and enforce our intellectual property rights, our business could be harmed. 🔒